Long-term safety study of palovarotene in FOP patients
Part of Bones, joints & muscles clinical trials.
This study tracks the long-term safety and how well palovarotene works in people with FOP who are already taking it as part of their regular care. By joining, you help doctors learn more about the medicine over time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You (or your child) have been diagnosed with fibrodysplasia ossificans progressiva (FOP).
- Your doctor has already prescribed palovarotene for you, and this decision was made before considering this study.
- You are not currently in another clinical trial for FOP (including a palovarotene trial).
- You do not have any medical reason that would make taking palovarotene unsafe (except for certain pregnancy cases).
- You (or your parent/guardian) agree to sign a consent form to participate.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is for people with FOP who have severe, frequent flare-ups. It follows those who are already starting an anti-IL1 medication (like anakinra) to see if it helps reduce flares and improve symptoms.
This is a follow-up study for patients who previously received RP-L102, an experimental gene therapy designed to treat Fanconi anemia by fixing a faulty gene. The study tracks how well the treatment continues to work and watches for any long-term side effects.
This trial is a registry that collects information from people with fibrodysplasia ossificans progressiva (FOP). It helps researchers better understand the condition and use that knowledge for future studies that could lead to better care.
This Phase 2 study tests whether INCB000928 can safely help people with fibrodysplasia ossificans progressiva (FOP). It mainly looks at whether the treatment is effective and well-tolerated, and it involves scheduled whole-body scans using low-dose X-rays.
This study tests whether garetosmab, a new medication, can slow or stop abnormal bone formation in children with FOP (a rare condition where muscle and connective tissue gradually turn into bone). The goal is to help young people with FOP move better and have fewer joint limitations.
This study follows patients with PFIC (a rare liver disease affecting bile flow) who are taking or planning to take odevixibat (Bylvay), a medication that helps manage the condition. Researchers will track how well the medication works, any side effects, and long-term health outcomes in Chinese patients.
Hear when a new Fibrodysplasia Ossificans Progressiva trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.